What causes hair loss after initiating GLP‑1 receptor agonist therapy (e.g., semaglutide, liraglutide, dulaglutide, tirzepatide) and how should it be managed?

Hair Loss on GLP-1 Receptor Agonists

Hair loss associated with GLP-1 receptor agonists is an emerging adverse effect that appears to be primarily telogen effluvium related to rapid weight loss and nutritional deficiencies, rather than a direct drug toxicity—reassure patients this is typically temporary and self-limited while optimizing nutrition and monitoring micronutrient status.

Understanding the Mechanism

The hair loss seen with GLP-1 RAs (semaglutide, liraglutide, tirzepatide, dulaglutide) is not listed as a recognized adverse effect in FDA drug labels 1, 2. However, pharmacovigilance data reveals over 1,000 spontaneous reports in the FDA Adverse Event Reporting System, with alopecia ranking as the fifth most common cutaneous reaction across all GLP-1 agonists 3.

The most likely culprits are:

• Rapid weight loss: GLP-1 RAs produce 6-20% body weight reduction over 12-72 weeks 4—weight loss of this magnitude and speed triggers telogen effluvium through metabolic stress
• Nutritional deficiencies: Users consume below estimated requirements for key nutrients, with vitamin D deficiency in 7.5-13.6%, iron depletion showing 26-30% lower ferritin levels, and over 60% consuming inadequate calcium and iron 5
• Protein insufficiency: Inadequate protein intake during rapid weight loss directly impacts hair follicle cycling 5

Recent scoping reviews identified telogen effluvium and androgenetic alopecia as the most frequent clinical patterns when dermatological assessment was performed 6.

Clinical Approach

Initial Assessment

When a patient on GLP-1 RA reports hair loss, evaluate:

• Timing: Hair loss typically begins 3-6 months after initiation (consistent with telogen effluvium physiology)
• Pattern: Diffuse thinning across the scalp rather than focal patches
• Weight loss velocity: Faster weight loss correlates with higher risk
• Dietary intake: Specifically assess protein (aim ≥60-75g daily), iron, vitamin D, calcium, thiamine, and B12

Laboratory Evaluation

Order targeted testing based on risk:

• Ferritin (most commonly depleted) 5
• Vitamin D (deficient in 7.5-13.6% of users) 5
• Complete blood count (assess for anemia)
• Vitamin B12 and thiamine (deficits increase over time) 5
• Thyroid function (if clinically indicated)

Management Strategy

1. Reassurance first: Explain this is likely telogen effluvium from rapid metabolic change, typically self-resolving over 6-12 months after hair follicles re-enter growth phase

2. Nutritional optimization:

   • Increase protein intake to 1.2-1.5 g/kg ideal body weight daily
   • Supplement identified deficiencies (vitamin D, iron, B vitamins)
   • Consider prophylactic multivitamin with minerals for all GLP-1 RA users given the high prevalence of inadequate intake 5

3. Medication decision: Do not discontinue GLP-1 RA unless hair loss is severe and distressing to the patient—the cardiovascular and metabolic benefits (13% reduction in cardiovascular death/MI/stroke) 4 far outweigh this cosmetic concern that will likely resolve with nutritional support

4. Slow titration: If not yet at target dose, consider slower dose escalation to moderate weight loss velocity

Critical Pitfalls to Avoid

• Don't assume direct drug toxicity: No positive pharmacovigilance signal was detected despite reports 7—this distinguishes GLP-1 RA hair loss from true drug-induced alopecia
• Don't overlook nutrition: The evidence strongly implicates nutritional deficiency as the primary mechanism 5, yet dietary assessment is almost never performed in clinical trials 8
• Don't stop the medication prematurely: The proven mortality benefit and cardiovascular protection 4 should take precedence over temporary cosmetic effects
• Don't order extensive dermatologic workup: Unless the pattern is atypical (patchy, scarring, or accompanied by scalp inflammation), this is a clinical diagnosis

Evidence Quality Note

While over 1,000 cases are reported in FAERS 6, no positive disproportionality signal was detected in comprehensive pharmacovigilance analysis 7, meaning the reporting rate doesn't exceed what would be expected by chance. The conflicting findings across studies 9 and lack of dermatological confirmation in most reports 6 suggest this is a secondary effect of the metabolic changes these drugs produce rather than a direct adverse drug reaction.